Twist Bioscience (NASDAQ:TWST) Director Melissa Starovasnik Sells 1,000 Shares of Stock

Twist Bioscience Corporation (NASDAQ:TWST) Director Melissa Starovasnik sold 1,000 shares of the company’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $51.00, for a total transaction of $51,000.00. Following the sale, the director directly owned 25,722 shares of the company’s stock, valued at approximately $1,311,822. This trade represents a 3.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Twist Bioscience Price Performance

Shares of NASDAQ TWST opened at $50.21 on Friday. The stock has a fifty day moving average price of $46.99 and a 200 day moving average price of $37.29. The company has a current ratio of 3.78, a quick ratio of 3.37 and a debt-to-equity ratio of 0.03. Twist Bioscience Corporation has a 12-month low of $23.30 and a 12-month high of $57.88. The company has a market cap of $3.08 billion, a P/E ratio of -39.23 and a beta of 2.20.

Twist Bioscience (NASDAQ:TWST) last issued its quarterly earnings data on Monday, February 2nd. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.02). Twist Bioscience had a negative return on equity of 27.16% and a negative net margin of 19.56%.The company had revenue of $103.70 million for the quarter, compared to analyst estimates of $100.32 million. The business’s revenue was up 16.9% compared to the same quarter last year. Research analysts anticipate that Twist Bioscience Corporation will post -2.12 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have issued reports on TWST. Robert W. Baird set a $50.00 price objective on shares of Twist Bioscience in a research report on Tuesday, February 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of Twist Bioscience in a research note on Friday, March 27th. Barclays raised their price target on shares of Twist Bioscience from $39.00 to $50.00 and gave the company an “overweight” rating in a report on Tuesday, February 3rd. TD Cowen reaffirmed a “buy” rating on shares of Twist Bioscience in a research note on Thursday, January 8th. Finally, Guggenheim boosted their price objective on shares of Twist Bioscience from $50.00 to $55.00 and gave the stock a “buy” rating in a report on Monday, March 30th. Seven research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, Twist Bioscience has a consensus rating of “Moderate Buy” and a consensus target price of $46.50.

Hedge Funds Weigh In On Twist Bioscience

A number of institutional investors have recently made changes to their positions in TWST. ARK Investment Management LLC grew its position in shares of Twist Bioscience by 12.4% during the fourth quarter. ARK Investment Management LLC now owns 7,559,495 shares of the company’s stock worth $239,787,000 after buying an additional 832,687 shares in the last quarter. Artisan Partners Limited Partnership raised its holdings in Twist Bioscience by 26.7% in the third quarter. Artisan Partners Limited Partnership now owns 6,410,900 shares of the company’s stock valued at $180,403,000 after acquiring an additional 1,349,867 shares in the last quarter. William Blair Investment Management LLC raised its holdings in Twist Bioscience by 43.7% in the fourth quarter. William Blair Investment Management LLC now owns 5,954,429 shares of the company’s stock valued at $188,874,000 after acquiring an additional 1,812,146 shares in the last quarter. EdgePoint Investment Group Inc. boosted its stake in Twist Bioscience by 31.7% during the 4th quarter. EdgePoint Investment Group Inc. now owns 5,377,991 shares of the company’s stock valued at $170,590,000 after acquiring an additional 1,295,672 shares during the last quarter. Finally, State Street Corp boosted its stake in Twist Bioscience by 17.4% during the 4th quarter. State Street Corp now owns 3,627,818 shares of the company’s stock valued at $115,074,000 after acquiring an additional 538,755 shares during the last quarter.

About Twist Bioscience

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.